Table 1.
Characteristics of 13 authorized/approved COVID-19 vaccines as of April 21, 2021
| Vaccine Name(s) | Manufacturer(s) | Type | Country of Origin | Trial Phase with Published Data | Trial Time Frame | Age Group Tested |
|---|---|---|---|---|---|---|
| BNT162b2, Comirnaty | Pfizer-BioNTech, Fosun Pharma | mRNA | US, Germany | III | 7/27/2020—11/14/2020 | 16+ |
| mRNA-1273 | Moderna, National Institute of Allergy and Infectious Diseases | mRNA | US | III | 7/27/2020—10/23/2020 | 18+ |
| AZD1222, ChAdOx1 nCoV-19 | Oxford-AstraZeneca | Adenovirus | UK | I/II | 4/23/2020—11/4/2020 | 18+ |
| Sputnik V, Gam-COVID-Vac | Gamaleya Research Institute; Health Ministry of the Russian Federation | Recombinant adenovirus (rAd26, rAd5) | Russia | III | 9/7/2020—11/24/2020 | 18+ |
| Ad26.COV2.S, JNJ-78436735 | Johnson & Johnson’s Janssen Biotech | Nonreplicating viral vector | The Netherlands, US | I/IIa | 7/22/2020—11/7/2020 | 18–55, 65+ |
| CoronaVac | Sinovac Biotech | Inactivated (formalin with alum adjuvant) | China | I/II | Phase I: 4/16/2020—4/25/2020 Phase II: 5/3/2020—5//5/2020 |
18–59 |
| BBIBP-CorV | China National Pharmaceutical Group (Sinopharm); Beijing Institute of Biological Products | Inactivated | China | I/IIa | 5/18/2020—7/30/2020 | 18–59 |
| EpiVacCorona | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology | Peptide | Russia | I/IIa | 7/27/2020—Present | 18–60 |
| Convidicea, Ad5-nCoV | CanSino Biologics | Recombinant (adenovirus type 5 vector) | China | III | 4/11/2020—4/16/2020 | 18+ |
| Covaxin, BBV152 | Bharat Biotech; Indian Council of Medical Research | Inactivated | India | I/II | 9/5/2020—9/12/2020 | 12–65 |
| WIBP-CorV | China National Pharmaceutical Group (Sinopharm); Wuhan Institute of Biological Products | Inactivated | China | I/II | 4/12/2020—5/2/2020 | 18–59 |
| CoviVac | Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products | Inactivated | Russia | I/IIa | N/A | N/A |
| ZF2001 | Anhui Zhifei Longcom Biopharmaceutical; Institute of Microbiology of the Chinese Academy of Sciences | Recombinant | China, Uzbekistan |
I/II | Phase I: 6/22/2020—7/3/2020 Phase II: 7/12/2020—7/17/2020 |
18–59 |
a
No data published yet as of April 22, 2021.